A randomized controlled study comparing the efficacy of tofacitinib and hydroxychloroquine in the treatment of new-onset palindromic rheumatism

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200061060

Enrollment

Unknown

Registered

2022-06-15

Start date

2022-06-01

Completion date

Unknown

Last updated

2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

palindromic rheumatism

Interventions

tofacitinib group:tofacitinib

hydroxychloroquine group:hydroxychloroquine

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years; 2. In line with the classification criteria of palindromic rheumatism proposed by Guerne and Weisman in 1992; 3. New-onset and treatment naive patients.

Exclusion criteria

Exclusion criteria: 1. Unwilling to participate in this researcher; 2. Severe hepatic and renal insufficiency; 3. Malignant tumor/infected patients; 4. Pregnant women or women planning to become pregnant within the follow-up period; 5. Patients diagnosed with rheumatic diseases; 6. Previous use of prednisone or immunosuppression.

Design outcomes

Primary

Measure	Time frame
remission rate;	—

Secondary

Measure	Time frame
SF-36;cytokine;side effects;Time to progression to other rheumatic diseases;	—

Countries

China

Contacts

Public ContactJunna Ye

Ruijin Hospital

yjn0912@qq.com+86 13817366731

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026